Literature DB >> 12457768

4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?

Mark A Giembycz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12457768     DOI： 10.1016/s0165-6147(02)02089-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  5 in total

Review 1.  An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.

Authors:  Mark A Giembycz
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 2.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

3.  BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Franziska Elena Herrmann; Christian Hesslinger; Lutz Wollin; Peter Nickolaus
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

Review 4.  Evaluation of PDE4 inhibition for COPD.

Authors:  Desuo Wang; Xiangli Cui
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

5.  Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice.

Authors:  Abigail Boyd; Ileana V Aragon; Justin Rich; Will McDonough; Marianna Oditt; Daniel Irelan; Edward Fiedler; Lina Abou Saleh; Wito Richter
Journal:  Biology (Basel)       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.